Work

Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives

Year: 2013
Type: review
Abstract: Hepatocellular carcinoma (HCC) is the sixth-most common malignancy diagnosed worldwide.1 Late-stage presentation, comorbidities, and limited donor availability enables only 10% of patients to receive curative therapies. Hence, there exists a critical need for novel treatments addressing HCC at all stages. During the last decade, several transarterial locoregional therapies have been developed. One of these, yttrium-90 (90Y) radioembolization, has matured into a recognized treatment option, with a demonstration of a clear palliative role by inducing necrosis and delaying progression.2-8 This overview will describe the biological rationale for 90Y, highlight seminal data, propose research questions, and discuss the future role of 90Y in HCC. HCC is a tumor that arises almost exclusively in cirrhosis caused by viruses, alcohol, or non-alcohol-related steatohepatitis, insulin-resistant metabolism, autoimmunity, and others. Therefore, survival of HCC patients is related to the tumor and underlying liver condition. In fact, genomic data coded in nontumoral cirrhotic tissue have shown the ability to determine risk of tumor recurrence after resection or ablation; this explains the tendency of HCC to recur and develop de novo tumor foci usually confined within the liver during the history of the disease.9 The observation that HCC is mostly a liver-limited cancer has allowed the development of a wide range of therapeutic strategies aimed at locoregional approaches and organ replacement by means of transplantation.10 Experience gained in recent years indicates that HCC is truly a radiosensitive tumor. External irradiation (electrons, protons, and carbon) produces significant tumor responses in patients with HCC.11 Limitations to its clinical applicability are determined by the coexisting intense radiosensitivity of normal liver tissue, precluding the irradiation of large liver volumes with doses >35-40 Gy.12 Intra-arterial (IA) radiation therapies were developed in an attempt to capitalize on the arterial perfusion of HCC, with the aim of delivering tumoricidal doses to liver tumors irrespective of number, size, and location (sparing normal parenchyma). Radioembolization is a term proposed by a panel of experts to define those procedures in which radioactive microspheres are injected IA for internal radiation purposes.13 It is the artery in which microspheres are injected that defines the volume of liver tissue exposed to radiation (intravascular brachytherapy). Contrary to transarterial chemoembolization (TACE), in which a combination of drug and ischemia are likely to drive the antitumor effect, 90Y effects are predominantly caused by the radiation effect, with a minor contribution from microembolization.14 Given this mechanism of action, patients with macrovascular invasion may be treated. The commercially available microspheres include resin (SIR-Spheres; SIRTeX Medical, Lane Cove, NSW, Australia) or glass (TheraSphere; Nordion, Ottawa, Ontario, Canada); both are loaded with 90Y, a pure beta emitter (i.e., no isolation or radioprotection). 90Y is a high-energy radiation source with a short half-life (2.67 days) and a short tissue penetration (2.5 mm). Within 2 weeks after injection, >95% of the radiation has been deposited. Glass and resin microspheres differ in several characteristics (specific activity and number of spheres). Despite these differences, clinical outcomes appear equivalent.15 The biological effects of radiotherapy are mediated by the absorbed dose (energy absorbed/unit mass). With 90Y, absorbed dose may be heterogeneous, depending on hemodynamics and variable intratumoral vessel density within each liver tumor.16 Despite this heterogeneity, most injected microspheres are preferentially absorbed into the tumor microvasculature in a 3:1 to 20:1 ratio, compared to the normal liver, with a preferential deposition in the periphery of nodules (dose, >500 Gy).17, 18 Exposure to radiation then produces irreversible cell damage in tumor epithelial, stromal, and endothelial cells (ECs) that ultimately leads to compromised tumor growth. In mouse models, radiation preferentially damages ECs of the gut microvasculature, suggesting that ECs may represent the principal targets for radiation and that the death of epithelial stem cells may be a secondary event in gastrointestinal (GI) toxicity.19 Similarly, it has been proposed that tumor cell death in response to radiotherapy may represent a secondary event after the death of ECs.20 High doses to hyperperfused tissue suggest that vessel damage may be key to the antitumoral effect of 90Y. Heterogeneous deposition of microspheres results in a variability of dosimetric considerations. In radioembolization, millions of 90Y sources are infused into the arterial vasculature. To predict ultimate 90Y deposition, a simulation angiogram is performed 1-2 weeks before treatment using 20-100 micron-sized technetium-99m-labeled macroaggregated albumin (Tc-MAA) particles. Planar and single-photon emission computed tomography (SPECT) gamma-camera imaging are then used to measure hepatopulmonary shunting to determine the average radiation dose that will be delivered to tumor and nontumor areas. There is variability in correlating between Tc-MAA and actual microsphere deposition (Spearman's correlation: 0.45-0.82).21 Furthermore, the resulting estimates reflect the average dose for a certain volume and not the actual dose, as calculated for external or interstitial radiotherapy. Historically, activity measured with intraoperative probes did correlate with the actual dose of radiation delivered and with Tc-MAA planar scintigraphy.22 Although the threshold absorbed dose resulting in objective tumor response remains a point of debate and depends on tumor type, vascularity, previous systemic agents, and use of radiosensitizers, tumor responses have been reported with doses as low as 40 Gy.23 These limitations in dosimetry do not impede the clinical use of 90Y. Tumor shrinkage occurs almost invariably after 90Y using the current methods for activity calculation.8, 13 Research concepts based on tumor and nontumor dosimetry methods applied to Tc-MAA planar and/or SPECT imaging have been proposed and await external validation.24, 25 As is well known with radiotherapy, it may take 3-6 months for the optimal response (i.e., size reduction) to manifest; consequently, median time to response is 6.6 (size) and 1.2 months (necrosis).3, 8, 26 Progression is often the result of new lesions (intra- or extrahepatic) or within the treated area, because microscopic nests of tumor cells are unlikely to have been affected by 90Y given their lack or arterialization.8 Reported median time to progression (TTP) ranges from 7.9 to 10.0 months (entire cohort) and from 11.8 to 15.5 months for patients with absent portal vein invasion.3, 27 However, given unpredictable tumor biology, early progression may be anticipated by baseline tumor characteristics (e.g., multinodularity, bilobar disease, vascular invasion, or elevated alpha-fetoprotein [AFP]).28 Identifying early progressors is important, because the role of systemic agents may be essential in improving long-term outcomes. Coexistence of HCC and cirrhosis affects 90Y outcomes in a manner similar to other treatments. Although vascular changes in the cirrhotic liver (arterioportal or venous shunts) may result in higher chances of technical contraindications, reduced functional reserve (increasing the risk of liver failure) after radiation mandates the adoption of technical methods maximizing parenchymal sparing.29 Imprecise dosimetry models that plague most arterial treatments hinder dose-tolerance analyses. In a three-dimensional liver model, absorbed dose was higher around the portal area than the central venules, potentially explaining the higher 90Y tolerance, compared to external beam irradiation.30 These models assume that microspheres are lodged in the distal arterial branches and uniformly scattered throughout the entire liver parenchyma without clustering. In contrast, microspheres can be found in portal and hepatic veins in normal liver and in fibrotic septa of cirrhotic livers, where they may form clusters and distribute heterogeneously. Hence, given these limitations, a precise dose-event relationship in liver tolerance remains elusive. Despite this, there is general agreement to limit the parenchymal dose to <50 Gy.7 Aside from isolated benign changes in liver function, a form of sinusoidal obstruction syndrome appearing 4-8 weeks after 90Y manifest as jaundice and mild ascites, and a moderate increase in gamma-glutamyl transpeptidase/alkaline phosphatase has been described in patients without cirrhosis as radioembolization-induced liver disease (REILD).31 This syndrome may also appear in 0%-33% of patients with cirrhosis treated in a whole-liver fashion and in 8%-15% of those in which only a partial volume is targeted.32 In the largest series published, grade 3 or higher bilirubin levels were observed within 3 months after therapy in 6%-14%.3, 7 Although a causal relationship could only be confirmed in controlled clinical trials, it is very likely that the increased bilirubin levels reflect some kind of REILD. This is further supported by the fact thcat increased bilirubin is not associated with changes in synthetic liver function (i.e., decreased albumin and prothrombin activity).7 Nonetheless, these findings underscore the acceptable safety profile of 90Y in HCC. Furthermore, other more-comprehensive definitions of liver decompensation in patients receiving 90Y may be considered. For instance, extending the recording of adverse events as potentially related to 6 months will provide a conservative estimate.33 Although such an extended definition of toxicity may inform prospective clinical trials on 90Y, it also gives rise to overestimations of REILD, because deterioration of liver function and performance status may occur in intermediate-advanced HCC, independently from any anticancer treatment. Over the last 10 years, there has been significant scientific advancement in the field of 90Y. Standardization of the practice and assessment of indications has transformed radioembolization from a procedure relying on local expertise to a routine procedure yielding predictable results in properly trained centers. Early series were limited by sample size, with a 43- and 24-patient series describing outcomes in small cohorts.6, 8, 28 Since then, seven well-controlled investigations establishing the safety and antitumoral effect of 90Y have been published; these will be presented temporally (Table 1). One of the common indications for 90Y that has emerged is HCC with portal venous thrombosis (PVT). Because 90Y is a microembolic procedure causing minimal occlusion of hepatic arteries, it may be safely used in the setting of PVT.34 This is a relevant clinical scenario, because PVT significantly increases the chances of extrahepatic spread.9 Given this interest, the first large-series analysis was a phase II study by Kulik et al. analyzing 90Y in 108 HCC patients with (34%) and without PVT (66%). Partial response rates of 42.2% (size) and 70% (necrosis) were reported.34 Survival varied by location of PVT and presence of cirrhosis. This study was important given its multicenter nature, challenging preconceived notions that embolotherapy could not be applied in the setting of PVT (ischemic hepatitis). Because 90Y is microembolic, this study reintroduced the idea of embolotherapy in the context of vascular invasion.14 Recently, mature long-term outcomes for PVT patients treated with 90Y in the sorafenib era were updated.35 It is unknown whether treating patients with PVT has any effect on metastatic dissemination, regardless of the response in the tumor thrombus. In 2010, a detailed review of the pathologic findings subsequent to 90Y treatment was presented by Riaz et al. in patients bridged or downstaged to transplantation.26 The intent was to examine the antitumoral effect of 90Y, a pathological proof of concept. This analysis demonstrated a very high rate (89%) of complete pathologic necrosis (CPN) in smaller lesions (1-3 cm) and a promising rate of CPN in larger lesions (65%; 3-5 cm) (independent pathology review). These data were compared to the CPN achieved in an identical pathology review of HCC after conventional TACE,36 confirming that 90Y could achieve better antitumoral effect (pathology), when compared with the standard of care (TACE), thereby introducing a new tool to the armamentarium of downstaging strategies. In 2010, the seminal experience from Northwestern University confirmed the positive outcomes of 291 patients with HCC treated with 90Y. This was a prospective, 5-year cohort study not only investigating long-term outcomes, but also presenting imaging follow-up, response rate (size and necrosis), TTP, and survival stratified by Child-Pugh, United Network for Organ Sharing (UNOS), and Barcelona Clinic Liver Cancer (BCLC). Child-Pugh A (with or without PVT) and Child-Pugh B (without PVT) potentially benefitted from treatment. TTP was longer for Child-Pugh A and B without PVT (15.5 and 13 months, respectively), when compared with those with PVT (5.6 and 5.9 months, respectively). As expected, survival was negatively affected by liver function (Child-Pugh A: 17.2 months; Child-Pugh B: 7.7 months; P = 0.002). TTP and overall survival (OS) varied by patient stage.3 Most important, this study was the first to outline, in a structured manner, expected response rate, TTP, and survival by Child-Pugh, UNOS, and BCLC. This granularity of detail in phase II has permitted hypothesis generation and statistical powering of 90Y studies. In the last few years, European studies have also confirmed the safety and efficacy of 90Y. Hilgard et al. analyzed 90Y in 108 consecutive patients with advanced HCC.27 They observed complete and partial response by necrosis criteria in 3% and 37%, respectively, with stable disease in 53%. TTP was 10.0 months, with OS of 16.4 months. This was the first study validating the technical reproducibility of outcomes, when compared to the 291-patient cohort. Also, clinical outcomes were similar, suggesting the consistent outcomes less dependent on local expertise, as previously considered. Finally, these findings provided a more compelling case for randomized, controlled trials (RCTs) with or without systemic agents in advanced HCC.37 The largest study of 90Y in HCC was published by Sangro et al. in 2011.7 This was a multicenter, retrospective cohort review of 325 patients. Median OS was 12.8 months (BCLC A: 24.4 months; BCLC B: 16.9 months; BCLC C: 10.0 months). Independent prognostic factors on multivariate analysis included performance status, tumor burden, international normalized ratio >1.2, and extrahepatic disease. Important observations were gained from this study. Despite its retrospective nature, this was the first study with a significant number of participating groups with reproducible data between centers (>8), validating multicenter feasibility in technically involved procedures. Also, data were very comparable to glass microspheres, confirming that radiation appears to be the dominant mechanism of action. Finally, outcomes data were displayed stratified by BCLC, critical for the design of clinical trials using this staging strategy.38, 39 BCLC guidelines suggest that TACE is the standard of care for patients with intermediate disease. Although this is universally recognized by clinicians caring for the HCC patient, investigators have challenged this notion, identifying possible subgroups within the intermediate stage and suggesting a role for 90Y in the same setting. Given the difficulties in performing randomized TACE versus 90Y studies, a large comparative effectiveness study was published in 2011.2 This compared 122 TACE and 123 90Y patients (toxicity, response, TTP, and survival). The groups were well balanced by Child-Pugh, UNOS, and BCLC, with older age in the 90Y cohort (P < 0.001). Findings included fewer transaminase elevations, a strong trend for better response (90Y: 49%; TACE: 36%; P = 0.052) and longer TTP with 90Y (90Y: 13.3 months; TACE: 8.4 months; P = 0.046). However, no survival difference could be identified (90Y: 20.5 months; TACE: 17.4 months; P = 0.232). Several important conclusions were drawn from this analysis. First, although there was no survival difference, radioembolization (outpatient procedure) was able to provide better disease control (longer TTP) with less toxicity than TACE (inpatient procedure). Second, although TTP has been suggested as a potential surrogate of survival, this study did not seem to provide compelling evidence in support of this contention. Finally, given the similarity of long-term survival outcomes, the findings brought into question the feasibility of a head-to-head comparative study between 90Y and TACE, requiring a 1,000-patient sample to demonstrate equivalence. Given the advent of sorafenib as the standard of care for patients progressing beyond intermediate disease, the feasibility of a statistically pure head-to-head (without crossover) comparison appears unlikely.38 Hence, most investigators have begun to 90Y for more advanced BCLC BCLC disease, because the secondary of 90Y, clinical of and have been feasibility studies. Most in the presented the prospective phase II study to 90Y in patients with intermediate or advanced Findings included a TTP of months and survival of months. patients were downstaged to resection advanced Furthermore, survival of PVT patients did not differ from intermediate patients. This study further the reproducibility of 90Y controlled investigations and survival outcomes in patients with liver function and vascular Given the lack of compelling clinical evidence the TACE sorafenib combination study recent in 90Y with sorafenib has been and the development of head-to-head and combination studies with sorafenib in patients with There to be clinical in 90Y as a treatment for HCC. However, of the has been challenging the of evidence with 90Y and a of be for 90Y into treatment Although the European of and the Cancer have recognized 90Y as a treatment option, the and European for the of the Liver have A recent at the Liver Cancer in the that have been several years when to the of evidence with 90Y to achieve the for These are It is that for new therapies to controlled research investigations are important factors include reproducibility and multicenter Furthermore, the feasibility of new approaches is important as is the of previously Given this of 90Y be Over the and a the use of radioactive microspheres for patients with HCC. To this in this was before the and adoption of BCLC the of the seminal studies establishing that TACE provided a survival and the of sorafenib This mechanism was at the there were no agents for HCC In European for 90Y in liver was also However, it was recognized that more randomized studies be to Hence, in an randomized phase 90Y with care in advanced HCC was During the review and the positive findings of sorafenib study were The HCC with sorafenib the standard of care in advanced The study was on However, given the compelling phase II evidence and safety profile in patients with the the for 90Y to include PVT.34 Therefore, in the the first for the treatment of advanced HCC was 90Y. This 40 years after the first in HCC using the same Despite these from the and research of HCC, the evidence for 90Y has to resulting in similar not survival in this 90Y is of the significant effects of These to treatment and dose or in studies, patients the of in the analysis of the phase median OS 108 patients with PVT receiving sorafenib was months and disease control rate was for patients with Child-Pugh A and PVT treated by 90Y (Table median OS between 10 and months with of Given this the limitations of studies, as well as the need for higher of several randomized, phase studies have been (Table of sorafenib in combination with local by in patients with carcinoma and of Intra-arterial in the of with Hepatocellular both 90Y when to of versus in Hepatocellular sorafenib versus radioembolization in advanced carcinoma and a prospective randomized clinical of 90Y radioembolization versus sorafenib for the treatment of advanced HCC with portal vein thrombosis all sorafenib to 90Y. These trials further the strong phase II resulting in advancement to phase trials in BCLC B disease are more challenging given the history of disease, large sample to demonstrate survival differences, as well as the that invariably occurs at In fact, some have suggested that survival is not an when subsequent therapies with survival studies are further with the survival time in intermediate patients treated with These observations further suggest that BCLC B is a with such survival in the feasibility of randomized studies versus This was by an review Despite this, of Radioembolization and in Hepatocellular is a randomized phase II TACE and 90Y in intermediate disease (Table Furthermore, the use of clinical and comparable subgroups within the intermediate stage will be in prospective using 90Y as the These will tumor in which of TACE results have such as Child-Pugh for after downstaging University of and performance One of the observations with 90Y is that as an it a when compared with TACE often patient with and The patient is for a from to for syndrome resulting from or arterial usually 1-2 weeks for overall depending on their baseline performance In 90Y a angiogram to and the vascular 90Y treatment also in often without the need for or Hence, for therapies and that the same in and in patient during the These were confirmed in a prospective phase II study TACE and 90Y using The study demonstrated that patients performance status to 90Y, 90Y TACE by As clinical experience has been gained with this several investigators have novel observations with 90Y. Although these have not been in the multicenter they are of clinical and of in this review The first novel to for HCC and is in to the ability of radiation doses to small of liver tissue than achieved using external this small of liver, usually for or but because of comorbidities, and liver can be using 90Y. The of liver with time and on imaging on the is observed in patients with disease potentially to curative but because of small future liver Although the of inducing is portal vein rates are in cirrhosis. In this patient treating the disease with 90Y to potentially important clinical The tumor is treated is not the as the HCC with a of portal venous with rates of in future and weeks for to be manifest mandates a of identifying those patients that be by Although the and of by 90Y is the of it is a fact that 90Y may anticancer and effects on the liver will efficacy to be in patients to approaches not only in HCC, but also in of liver 1). The novel the downstaging to liver To studies have demonstrated the ability of 90Y to patients from to The first series demonstrated a downstaging The a comparative effectiveness study in demonstrated better downstaging of 90Y, when compared with TACE versus P < This is by the high antitumoral effect of 90Y and size In comparative effectiveness a strong trend of response rate, when compared with TACE, was reported (90Y: 49%; TACE: 36%; P = High response rates by necrosis and size criteria have been suggesting that 90Y potential tool for downstaging Finally, 90Y could represent an to intermediate-advanced tumors within when tumor response 6 months has been supported by and These and in of with to indications for It is often that from a research 90Y is a that with TACE in BCLC because both are transarterial and the of However, this is not universally by HCC 90Y into a potential role in BCLC 90Y in BCLC A is in by higher compared to TACE, and by the concepts of and and downstaging For BCLC comparative studies are also because differences, as well as of at result in 1,000-patient Finally, in BCLC the effect on PVT observed with strong rationale for with and to 3 90Y indications and that are by Radioembolization a promising treatment challenging the current of HCC treatment. centers have provided compelling data that suggest high antitumoral effect, downstaging to clinical in TACE survival using an or of and of patients liver to potential with resection of the future liver Although clinical development has been the few years will important as results from the randomized phase trials further define the role of 90Y in treatment
Source: Hepatology
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: green
OpenAlex ID: W2166590925
FWCI: 2.576
Cites: 63
Cited by: 190
Related to: 10